Search research articles
Contact Us
Filters
Showing results (31-40 of 35) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 35 results.
Molecular Cell
|
June 2, 2007
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Tsung-Cheng Chang, Erik A Wentzel, Oliver A Kent, et al.
Nature
|
January 24, 2017
An Argonaute phosphorylation cycle promotes microRNA-mediated silencing
Ryan J Golden, Beibei Chen, Tuo Li, et al.
Cell Reports
|
October 18, 2023
ZNF692 organizes a hub specialized in 40S ribosomal subunit maturation enhancing translation in rapidly proliferating cells
M Carmen Lafita-Navarro, Yi-Heng Hao, Chunhui Jiang, et al.
Research Square
|
July 28, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature Communications
|
March 14, 2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 35) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 35 results.
Molecular Cell
|
June 2, 2007
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Tsung-Cheng Chang, Erik A Wentzel, Oliver A Kent, et al.
Nature
|
January 24, 2017
An Argonaute phosphorylation cycle promotes microRNA-mediated silencing
Ryan J Golden, Beibei Chen, Tuo Li, et al.
Cell Reports
|
October 18, 2023
ZNF692 organizes a hub specialized in 40S ribosomal subunit maturation enhancing translation in rapidly proliferating cells
M Carmen Lafita-Navarro, Yi-Heng Hao, Chunhui Jiang, et al.
Research Square
|
July 28, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature Communications
|
March 14, 2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Page
of 4